nivolumab

Open Access
Pre-treatment Tumor Size and Tumor Growth Rate as Prognostic Predictors for Patients With Recurrent/Metastatic Squamous Cell Carcinoma of the Head and Neck Treated With Nivolumab
YURI HIRAI, KEI KURIHARA, DAISUKE SANO, MANA INAMO, HIDEAKI TAKAHASHI, YASUSHI ICHIKAWA and NOBUHIKO ORIDATE

In Vivo November 2023, 37 (6) 2687-2695; DOI: https://doi.org/10.21873/invivo.13378
Open Access
Humanized PD-1 Knock-in Mice Reveal Nivolumab’s Inhibitory Effects on Glioblastoma Tumor Progression In Vivo
CHUN-YU CHIANG, MENG-CHU HUANG, SHIH-CHONG TSAI, FEI-TING HSU, TSAI-LAN LIAO, JEI-HWA YU, TZU-HSIANG LIN, HUA-HSIH HUANG and PEN-AN LIAO

In Vivo September 2023, 37 (5) 1991-2000; DOI: https://doi.org/10.21873/invivo.13296
Open Access
Serious Immune-related Adverse Events Are Associated With Greater Efficacy of Nivolumab Therapy Against Non-small Cell Lung Cancer
JIRI BLAZEK, PETR HOSEK, KAROLINA HRABCOVA, MONIKA BRATOVA, JURAJ KULTAN, MICHAL HRNCIARIK, MARKETA CERNOVSKA, PETRA ZEMANOVA, JANA KREJCI, LEONA KOUBKOVA, MAREK STASTNY and MARTIN SVATON

In Vivo September 2023, 37 (5) 2229-2236; DOI: https://doi.org/10.21873/invivo.13324
Open Access
Adverse Events in Patients With Esophageal Cancer Treated With Nivolumab in Combination With Radiotherapy
YASUSHI RINO, TORU AOYAMA, YUKIO MAEZAWA, KAZUKI KANO, MIHWA JU, HIROSHI TAMAGAWA, SHO SAWAZAKI, KEISUKE KAZAMA, HARUKA KANAI, TSUTOMU SATO, AYA SAITO and NORIO YUKAWA

In Vivo July 2023, 37 (4) 1760-1764; DOI: https://doi.org/10.21873/invivo.13264
Open Access
Immune Checkpoint Inhibitors for Nasopharyngeal Carcinoma in a Real-world Setting in Japan
TOMOMI MANAKO, RYUJI YASUMATSU, TAKAFUMI NAKANO, MIOKO MATSUO, TORANOSHIN TAKEUCHI, MASAHIKO TAURA, AKIHIRO TAMAE, MORIYASU YAMAUCHI, MUNEYUKI MASUDA, KENICHI TAGUCHI and TAKASHI NAKAGAWA

In Vivo March 2023, 37 (2) 747-755; DOI: https://doi.org/10.21873/invivo.13137
Open Access
Albumin–derived Neutrophil-to-Lymphocyte Ratio Score as a Marker of Nivolumab Treatment Sensitivity in Gastric Cancer: A Multicenter Study
NOBUHIRO NAKAZAWA, MAKOTO SOHDA, KOHEI TATENO, TAKAYOSHI WATANABE, AKIHARU KIMURA, NORIMICHI KOGURE, HISASHI HOSAKA, ATSUSHI NAGANUMA, MASANORI SEKIGUCHI, KANA SAITO, KYOICHI OGATA, AKIHIKO SANO, MAKOTO SAKAI, HIROOMI OGAWA, KEN SHIRABE and HIROSHI SAEKI

In Vivo March 2023, 37 (2) 818-824; DOI: https://doi.org/10.21873/invivo.13147
Open Access
Complete Response to Nivolumab of Resected Adenocarcinoma NOS With Parotid Gland Origin and Lung Metastasis
YUI NEGISHI, ISAKU OKAMOTO, YURI UEDA, HIROKI SATO, MAKI TANIGAWA, TOSHITAKA NAGAO and KIYOAKI TSUKAHARA

In Vivo November 2022, 36 (6) 2840-2843; DOI: https://doi.org/10.21873/invivo.13023
Open Access
Five-year Follow-up of Patients With Head and Neck Cancer Treated With Nivolumab and Long-term Responders for Over Two Years
MIOKO MATSUO, RYUJI YASUMATSU, MUNEYUKI MASUDA, MORIYASU YAMAUCHI, TAKAHIRO WAKASAKI, KAZUKI HASHIMOTO, RINA JIROMARU, TOMOMI MANAKO and TAKASHI NAKAGAWA

In Vivo July 2022, 36 (4) 1881-1886; DOI: https://doi.org/10.21873/invivo.12907
You have access
Inflammation-based Prognostic Score as a Prognostic Biomarker in Patients With Recurrent and/or Metastatic Head and Neck Squamous Cell Carcinoma Treated With Nivolumab Therapy
MIOKO MATSUO, RYUJI YASUMATSU, MUNEYUKI MASUDA, SATOSHI TOH, TAKAHIRO WAKASAKI, KAZUKI HASHIMOTO, RINA JIROMARU, TOMOMI MANAKO and TAKASHI NAKAGAWA

In Vivo March 2022, 36 (2) 907-917; DOI: https://doi.org/10.21873/invivo.12780
You have access
Changes in Chemotherapeutic Strategies and Their Prognostic Impact in Patients With Advanced Gastric Cancer
TAKAAKI ARIGAMI, DAISUKE MATSUSHITA, KEISHI OKUBO, TAKAKO TANAKA, KEN SASAKI, YUSUKE TSURUDA, YOSHIAKI KITA, SHINICHIRO MORI, HIROSHI KURAHARA, YOSHIKAZU UENOSONO and TAKAO OHTSUKA

In Vivo January 2022, 36 (1) 409-415; DOI: https://doi.org/10.21873/invivo.12718

Main menu

User menu

Search

nivolumab

Pages